Brian D. Lehmann - Concepedia

Author

Brian D. Lehmann

Also Known As

B D Lehmann, B Lehmann, B.D. Lehmann, Brian D Lehmann, Brian D. Lehmann, Brian David Lehmann, Brian Lehmann, Lehmann, Brian, Lehmann, Brian D., Sanders, Melinda E

307

Publications

15.7K

Citations

H-Index

Concepts

All Affiliations

Vanderbilt University Vanderbilt University Medical Center East Carolina University Dana-Farber Cancer Institute The University of Texas MD Anderson Cancer Center

About

Brian D. Lehmann is an author at Vanderbilt University specializing in medicine, cell biology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	20	7.8K
2	Engineering	4	4	212
3	Health Sciences	2	2	6.7K
4	Natural Sciences	1	1	23
5	Public Health	1	1	60

Brian D. Lehmann

Publications

11.9K

Citations

H-Index

Page 1

	Year	Citations
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies Brian D. Lehmann, Joshua A. Bauer, Xi Chen, Journal of Clinical Investigation Androgen ReceptorBreast OncologyTumor BiologyOncologyTumor Heterogeneity	2011	5.3K
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection Brian D. Lehmann, Bojana Jovanović, Xi Chen, PLoS ONE Breast OncologyPathologyNeoadjuvant Chemotherapy SelectionTumor BiologyOncology	2016	1.3K
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes Hiroko Masuda, Keith Baggerly, Ying Wang, Clinical Cancer Research	2013	700
Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets Justin M. Balko, Jennifer M. Giltnane, Kai Wang, Cancer Discovery	2013	467
Senescence-Associated Exosome Release from Human Prostate Cancer Cells Brian D. Lehmann, Matthew S. Paine, Adam M. Brooks, Cancer Research	2008	461
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors Brian D. Lehmann, Joshua A. Bauer, Johanna M. Schafer, Breast Cancer Research	2014	315
TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer Xi Chen, Jiang Li, W.H. Gray, Cancer Informatics	2012	276
Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes Brian D. Lehmann, Antonio Colaprico, Tiago C. Silva, Nature Communications	2021	244
BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition Katherine E. Hutchinson, Doron Lipson, Philip J. Stephens, Clinical Cancer Research	2013	176
Triple-Negative Breast Cancer: Molecular Subtypes and New Targets for Therapy Brian D. Lehmann, Jennifer A. Pietenpol, Antoinette R. Tan American Society of Clinical Oncology Educational Book	2015	174

Page 1